Dr. Richardson on Isatuximab Triplet Regimen in Relapsed/Refractory Myeloma

Paul G. Richardson, MD
Published: Tuesday, Jun 04, 2019



Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

Isatuximab is a CD38-targeted antibody, which demonstrates single-agent activity and activity in combination with other agents. This is the first trial of its kind combining isatuximab with pomalidomide/dexamethasone compared with pomalidomide/dexamethasone alone. Results showed that the progression-free survival, response rate, quality of response, and a higher minimal residual disease–negative rate was superior with the addition of isatuximab versus pomalidomide and dexamethasone alone. 

Time to next therapy, one of the secondary endpoints, also favored the triplet regimen. There were no safety signals, and there was no detriment to the quality-of-life measures with the 3-drug regimen compared with pomalidomide/dexamethasone alone, says Richardson.

<<< 2019 ASCO Annual Meeting


Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

Isatuximab is a CD38-targeted antibody, which demonstrates single-agent activity and activity in combination with other agents. This is the first trial of its kind combining isatuximab with pomalidomide/dexamethasone compared with pomalidomide/dexamethasone alone. Results showed that the progression-free survival, response rate, quality of response, and a higher minimal residual disease–negative rate was superior with the addition of isatuximab versus pomalidomide and dexamethasone alone. 

Time to next therapy, one of the secondary endpoints, also favored the triplet regimen. There were no safety signals, and there was no detriment to the quality-of-life measures with the 3-drug regimen compared with pomalidomide/dexamethasone alone, says Richardson.

<<< 2019 ASCO Annual Meeting



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x